Gastro Education 2018
Journal of Clinical Gastroenterology and Hepatology
ISSN: 2575-7733
Page 26
September 06-07, 2018
London, UK
14
th
International Conference on
Gastro Education
P
ancreatic cancer accounts for 3%of all cancers, is the 3rdmost
common cause of cancer death, has a 30month survival of the
tumourwhich is less than1cm indiameter, less than1%of patients
benefit from surgery and 20% of patients who undergo Whipple’s
procedure survive for 5 years. Two radiofrequency devices
were invented by an Imperial College London spin out company,
Emcision Limited (recently acquired by Boston Scientific Inc)
trying to treat inperable pancreatic cancers using an endoscopic
approach. The EndoHPB (Endoscopic Bipolar Radiofrequency
Probe) is a bipolar device delivered endoscopically that has been
shown in three different studies to improve survival following
radiofrequency ablation prior to biliary stent placement. The EUS-
RFA (Endoscopic uitrasound guided radiofrequency ablation)
device is a monoplar radiofrequnecy device which is delivered
using echoendoscope. In a a multi-centre, pilot safety study
in 8 patients 6 had pancreatic cystic neoplasm and two had a
neuroendocrine tumours (NET) in the head of pancreas. EUS-RFA
was successfully completed in all cases. Among the 6 patients
with a cystic neoplasm, post procedure imaging in 3-6 months
showed complete resolution of the cysts in 2 cases, whilst in three
more there was a 48.4% reduction in size. In the NET patients,
there was a change in vascularity and central necrosis after EUS-
RFA. No major complications were observed within 48 h of the
procedure. This preliminary data suggest that the procedure is
straightforward and safe. The response ranged from complete
resolution to a 50% reduction in size.
Biography
Nagy Habib is the Head of Surgery at the Hammersmith Campus of Imperial
College London, UK. He is a Translational Researcher who pioneered the first
clinical trial of the use of plasmid and adenovirus for the treatment of liver
cancer, as well as the use of plasmid gene therapy in hydrodynamic gene
delivery. He is the Principal Investigator of world first clinical trials published
on the use of adult bone marrow-derived stem cells for the treatment of pa-
tients with liver insufficiency and CD34+ cells for patients with stroke. He is
the Inventor and Co-author on the first publication to describe the use of ra-
diofrequency energy in devices for liver surgery (Habib 4X), and interventional
endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA).
nagy.habib@imperial.ac.ukEndoscopic radiofrequency ablation for biliary and Pancreatic
cancers
Nagy Habib
Imperial College London, UK
Nagy Habib, J Clin Gastroenterol Hepatol 2018, Volume 2
DOI: 10.21767/2575-7733-C2-006




